Volume 30, Issue 6 946295 pp. 325-333
Article
Open Access

Crosstalk between Activated and Inactivated c-Src in Hepatocellular Carcinoma

Mei-Lin Chen

Mei-Lin Chen

Department of Pathology Changhua Christian Hospital Changhua, Taiwan , cch.org.tw

Search for more papers by this author
Chee-Yin Chai

Chee-Yin Chai

Department of Pathology Kaohsiung Medical University Hospital Kaohsiung, Taiwan , kmu.edu.tw

Department of Pathology Faculty of Medicine College of Medicine Kaohsiung Medical University Kaohsiung, Taiwan , kmu.edu.tw

Search for more papers by this author
Kun-Tu Yeh

Kun-Tu Yeh

Department of Pathology Changhua Christian Hospital Changhua, Taiwan , cch.org.tw

Search for more papers by this author
Shen-Nien Wang

Shen-Nien Wang

Graduate Institute of Medicine Kaohsiung Medical University Kaohsiung, Taiwan , kmu.edu.tw

Division of Hepatobiliary Surgery Department of Surgery Kaohsiung Medical University Hospital Kaohsiung, Taiwan , kmu.edu.tw

Search for more papers by this author
Chia-Jung Tsai

Chia-Jung Tsai

Graduate Institute of Medicine Kaohsiung Medical University Kaohsiung, Taiwan , kmu.edu.tw

Department of Medical Laboratory Science and Biotechnology Fooyin University Kaoshiung, Taiwan , fy.edu.tw

Search for more papers by this author
Yao-Tsung Yeh

Corresponding Author

Yao-Tsung Yeh

Department of Medical Laboratory Science and Biotechnology Fooyin University Kaoshiung, Taiwan , fy.edu.tw

Search for more papers by this author
Sheau-Fang Yang

Corresponding Author

Sheau-Fang Yang

Department of Pathology Kaohsiung Medical University Hospital Kaohsiung, Taiwan , kmu.edu.tw

Department of Pathology Faculty of Medicine College of Medicine Kaohsiung Medical University Kaohsiung, Taiwan , kmu.edu.tw

Search for more papers by this author
First published: 28 May 2013

Abstract

C-Src activity is regulated by tyrosine phosphorylation at two distinct sites, Tyr416 and Tyr527, with opposite effects. However, the clinical roles of these sites in human cancers are not well defined. This study aims to determine whether the alterations and crosstalk of these two sites may contribute to hepatocellular carcinoma (HCC). Specimens from 85 patients who had undergone curative hepatectomy were collected for this study. The patterns of p-Tyr416-Src and p-Tyr527-Src, as well as the non-phosphorylated status for each site, were determined using immunohistochemistry and statistically correlated with clinicopathological characteristics and overall survival rate. The active state of c-Src, p-Tyr416-c-Src, was positively correlated with tumour grade (P = 0.062) but inversely correlated with vascular invasion (P = 0.071). Its non-phosphorylated status, non-p-Tyr416-c-Src, was positively correlated with tumour stage and grade (P = 0.041 and 0.020). The inactive state of c-Src, p-Tyr527-c-Src, was decreased in male patients but increased HCV-infected patients (P = 0.044 and 0.033). The Kaplan-Meier survival curve further showed that increased p-Tyr416-c-Src and decreased non-p-Tyr527-c-Src expression were associated with a poor patient survival rate (P = 0.004 and 0.025). Interestingly, the expression of non-p-Tyr416-c-Src was positively correlated with that of p-Tyr527-c-Src in the HCC lesions (P = 0.040). In addition, the patients with concomitantly low p-Tyr416-c-Src and non-p-Tyr527-c-Src expression had a prolonged overall survival rate (P = 0.030). A multivariable COX regression model showed that p-Tyr416-c-Src expression was an effective predictor for patient survival in HCC [OR = 3.78, 95%CI = 1.46–9.76; P = 0.006]. Our results suggest that the active state of c-Src, p-Tyr416-c-Src, may serve as an independent prognostic marker of patient survival in HCC. Relative levels of other phosphorylated or non-phosphorylated c-Src kinases may also present different statuses during HCC development and require further investigation.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.